<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136470</url>
  </required_header>
  <id_info>
    <org_study_id>BioForte</org_study_id>
    <secondary_id>POIR.01.01.01-00-0347/17</secondary_id>
    <nct_id>NCT04136470</nct_id>
  </id_info>
  <brief_title>BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics</brief_title>
  <official_title>Development of BioForte Technology for in Silico Identification of Valuable Genomic Features That Are Candidates for Microbiome-based Therapeutics and Diagnostics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The National Centre for Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardigen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to develop and validate the BioForte technology. Its main
      functionality should be to in silico determine candidates for novel microbiome-based
      therapeutics and diagnostics. Key challenge to be solved using the technology is to detect
      the differences in gut microbiome between oncology patients who respond to immunotherapies
      and the ones who do not respond to this treatment.

      This technology employs machine learning methods to replace the laboratory procedure for
      finding valuable genomic features. Such features can be crucial to identify differences
      between the two populations (e.g. responders vs non-responders) to target specific strains.

      The samples and data collected in this clinical study will be used for clinical validation of
      BioForte technology. For all patients treated with immunotherapy, stool collection will be
      performed per patient (one stool collection before setting up immunotherapy using anti-PD1 /
      anti-PDL1 and / or anti CTLA4 antibodies). Samples will be sequenced by long-read sequencing
      technology. In parallel, we will also collect samples of peripheral blood samples (PBMC) and
      biopsy (FFPE).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial diversity in stool samples</measure>
    <time_frame>Inclusion</time_frame>
    <description>Microbila DNA - stool samples sequenced by long-read sequencing technology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Responders and Non-responders on immunotherapy (evaluated using RECIST 1.1 criteria)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Standard follow-up care after cancer treatment.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Microbiome</condition>
  <condition>Metagenome</condition>
  <condition>Immunotherapy</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>NSCLC</arm_group_label>
    <description>This cohort will consist of 100 patients with non-small cell lung cancer (NSCLC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEL</arm_group_label>
    <description>This cohort will consist of 30 patients with melanoma (MEL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collection of stool, blood (PBMC) and biopsy (FFPE)</intervention_name>
    <description>Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).</description>
    <arm_group_label>MEL</arm_group_label>
    <arm_group_label>NSCLC</arm_group_label>
    <other_name>Nivolumab</other_name>
    <other_name>Ipilimumab</other_name>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      stool, biopsy (FFPE) and peripheral blood samples (PBMC)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving routine treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥18 years of age.

          -  Patients with one of the following types of cancer: non-small cell lung cancer,
             melanoma.

          -  Patients with informed consent to participate in the study.

          -  Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and /
             or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).

          -  The applied immunotherapy should be the first or second line of treatment.

        Exclusion Criteria:

          -  Patients who are unable to understand, read and / or sign informed consent.

          -  Patients who can not collect stools.

          -  Patients with fecal transplant.

          -  The applied immunotherapy is not the first or second line of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Warchol, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ardigen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilia Strycharz-Angrecka</last_name>
    <phone>+48 12 340 94 94</phone>
    <email>emilia.strycharz-angrecka@ardigen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bozena Augustyn</last_name>
    <phone>+48 12 340 94 94</phone>
    <email>bozena.augustyn@ardigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Centre in Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The John Paul II Hospital in Krakow</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Maria Sklodowska-Curie National Research Institute of Oncology Krakow Branch</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poznań University Hospital of Lord's Transfiguration</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Provincial Hospital St. Father Pio in Przemyśl</name>
      <address>
        <city>Przemyśl</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mountains Center of Pulmonology and Chemotherapy &quot;Izer-Med&quot;</name>
      <address>
        <city>Szklarska Poręba</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masovian Oncology Hospital in Wieliszew</name>
      <address>
        <city>Wieliszew</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lower Silesian Oncology Center &amp; Łukasiewicz Research Network - PORT Polish Center For Technology Development</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metagenome</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Stool</keyword>
  <keyword>FFPE</keyword>
  <keyword>PBMC</keyword>
  <keyword>Intestinal microbiota</keyword>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

